9,279 Shares in Astrazeneca Plc $AZN Purchased by Tlwm

Tlwm purchased a new stake in Astrazeneca Plc (NYSE:AZN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 9,279 shares of the company’s stock, valued at approximately $1,759,000. Astrazeneca accounts for about 0.3% of Tlwm’s portfolio, making the stock its 29th largest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mascoma Wealth Management LLC purchased a new position in shares of Astrazeneca in the 1st quarter valued at approximately $26,000. MV Capital Management Inc. acquired a new position in shares of Astrazeneca in the fourth quarter valued at approximately $26,000. Roxbury Financial LLC purchased a new stake in shares of Astrazeneca during the second quarter worth approximately $29,000. Reflection Asset Management purchased a new stake in shares of Astrazeneca during the fourth quarter worth approximately $31,000. Finally, Resources Management Corp CT ADV acquired a new stake in shares of Astrazeneca during the first quarter worth $35,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AZN. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Weiss Ratings downgraded shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Finally, Bank of America restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Astrazeneca Price Performance

Shares of NYSE:AZN opened at $161.41 on Thursday. The firm has a market capitalization of $250.34 billion, a price-to-earnings ratio of 24.13, a price-to-earnings-growth ratio of 1.34 and a beta of 0.26. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. The business’s 50 day simple moving average is $177.32 and its 200-day simple moving average is $187.40. Astrazeneca Plc has a 12 month low of $145.79 and a 12 month high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.Astrazeneca’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the business posted $2.17 EPS. As a group, equities analysts forecast that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: A senior source told Reuters that AstraZeneca and Bristol Myers Squibb are not discussing a transaction, effectively quashing the merger rumor. Investors appear to view the clarification favorably because it removes uncertainty surrounding deal financing, valuation and integration risks. Reuters report on AstraZeneca-Bristol Myers deal discussions
• Positive Sentiment: AstraZeneca rebounded after the reports denied Bristol Myers takeover speculation. The shares had suffered a roughly 9% single-day selloff when the merger story first emerged, making the subsequent recovery a relief rally as investors reassessed the company’s standalone prospects. AZN rebound after merger denial
• Positive Sentiment: Traders purchased a high volume of AstraZeneca call options, indicating increased speculative interest and expectations for additional near-term gains or volatility following the merger-related selloff. AstraZeneca call option activity
• Positive Sentiment: AstraZeneca also entered a multi-year collaboration with SOPHiA GENETICS to develop companion diagnostics for two precision-oncology therapy programs. The agreement supports the company’s targeted-cancer strategy, although its immediate financial impact is unclear. SOPHiA GENETICS collaboration announcement
• Neutral Sentiment: Analysts remain divided on the strategic implications of the abandoned merger speculation. Citi said much of the deal-related risk was already reflected in AstraZeneca’s valuation, while other analysts compared the potential transaction with AstraZeneca’s earlier Alexion acquisition.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of AstraZeneca investors. Such investor-alert announcements can add reputational and legal overhang, though no wrongdoing has been established. Pomerantz AstraZeneca investor alert

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.